SIRT1 and pulmonary arterial hypertension: Therefore, targeting SIRT1 activity through the restoration of mitochondrial biogenesis and normalization of the PASMC phenotype may represent a novel therapeutic approach to inhibit PASMC proliferation and delay the progression of PAH [8].